| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$62,896 ) |
| | 2023 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44DA042639 | Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch | 000 | 2 | NIH | 8/9/2023 | -$62,896 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R01AG067972 | Food Effect study and drug supply scale-up for PTI-125 | 000 | 1 | NIH | 5/19/2022 | $0 |
| | 2022 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 001 | 3 | NIH | 11/1/2021 | $0 |
| | 2022 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 002 | 3 | NIH | 5/9/2022 | $0 |
| | 2022 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 000 | 3 | NIH | 10/15/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,710,220 ) |
| | 2021 | 2021 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R01AG067972 | Food Effect study and drug supply scale-up for PTI-125 | 000 | 1 | NIH | 5/10/2021 | $2,710,220 |
| | 2021 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG065152 | Open-label extension of a 3-month blinded clinical trial of PTI-125 | 000 | 1 | NIH | 7/13/2021 | $0 |
| | 2021 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44DA042639 | Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch | 000 | 2 | NIH | 6/1/2021 | $0 |
| | 2021 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 000 | 2 | NIH | 8/5/2021 | $0 |
| | 2021 | 2018 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 000 | 3 | NIH | 1/27/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,324,538 ) |
| | 2020 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 000 | 3 | NIH | 1/23/2020 | $450,142 |
| | 2020 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG065152 | Open-label extension of a 3-month blinded clinical trial of PTI-125 | 000 | 1 | NIH | 4/22/2020 | $2,499,896 |
| | 2020 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG065152 | Open-label extension of a 3-month blinded clinical trial of PTI-125 | 001 | 1 | NIH | 5/5/2020 | $0 |
| | 2020 | 2020 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 000 | 2 | NIH | 3/6/2020 | $374,500 |
|
| Issue Date FY: 2019 ( Subtotal = $5,885,348 ) |
| | 2019 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44DA042639 | Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch | 001 | 2 | NIH | 8/15/2019 | $1,879,039 |
| | 2019 | 2019 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 000 | 2 | NIH | 12/12/2018 | $2,896,561 |
| | 2019 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 002 | 2 | NIH | 4/10/2019 | $235,267 |
| | 2019 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 001 | 2 | NIH | 8/29/2019 | -$1,109,748 |
| | 2019 | 2019 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 001 | 2 | NIH | 8/29/2019 | $1,109,748 |
| | 2019 | 2019 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 000 | 2 | NIH | 1/14/2019 | $1,109,748 |
| | 2019 | 2018 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 001 | 1 | NIH | 4/10/2019 | -$235,267 |
| | 2019 | 2018 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 001 | 3 | NIH | 9/7/2019 | $0 |
| | 2019 | 2017 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 000 | 2 | NIH | 3/15/2019 | $0 |
| | 2019 | 2017 | CASSAVA SCIENCES, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44DA042639 | Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch | 000 | 1 | NIH | 8/9/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $3,881,405 ) |
| | 2018 | 2018 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 002 | 3 | NIH | 9/20/2018 | $350,000 |
| | 2018 | 2018 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 001 | 3 | NIH | 9/12/2018 | $2,896,320 |
| | 2018 | 2018 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 000 | 1 | NIH | 8/13/2018 | $260,585 |
| | 2018 | 2018 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG060878 | Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate | 001 | 1 | NIH | 9/20/2018 | $374,500 |
| | 2018 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 000 | 1 | NIH | 12/15/2017 | $0 |
| | 2018 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R42AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 000 | 1 | NIH | 5/8/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $2,512,038 ) |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 002 | 2 | NIH | 9/11/2017 | $1,500,000 |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 001 | 1 | NIH | 8/1/2017 | $0 |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 000 | 1 | NIH | 5/31/2017 | $225,000 |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44DA042639 | Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch | 000 | 1 | NIH | 8/30/2017 | $349,947 |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R42AG057329 | Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease | 000 | 1 | NIH | 8/29/2017 | $295,343 |
| | 2017 | 2017 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG056166 | Solid oral dosage form and chronic tox for PTI-125 | 003 | 2 | NIH | 9/13/2017 | $141,748 |
| | 2017 | 2016 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG050301 | IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease | 001 | 2 | NIH | 3/20/2017 | $0 |
| | 2017 | 2015 | PAIN THERAPEUTICS, INC. | 7801 N CAPITAL OF TEXAS HWY STE 260 | AUSTIN | TX | 78731-1192 | TRAVIS | USA | R44AG050301 | IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease | 000 | 1 | NIH | 3/20/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,500,000 ) |
| | 2016 | 2016 | PAIN THERAPEUTICS INC | 416 BROWNING WAY | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R44AG050301 | IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease | 001 | 2 | NIH | 1/8/2016 | $1,500,000 |
| | 2016 | 2015 | PAIN THERAPEUTICS INC | 416 BROWNING WAY | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R44AG050301 | IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease | 000 | 1 | NIH | 1/6/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $225,000 ) |
| | 2015 | 2015 | PAIN THERAPEUTICS INC | 416 BROWNING WAY | SOUTH SAN FRANCISCO | CA | 94080 | SAN MATEO | USA | R44AG050301 | IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease | 000 | 1 | NIH | 7/29/2015 | $225,000 |
|
|
